Last updated: July 18, 2026
- Case: Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc., 2:23-cv-02684 (filed 2023; District court docket number format indicates D.N.J.).
- Status: No litigation merits details (claims, asserted patents, court rulings, settlement terms, or scheduled dates) are available in the provided record, so a complete, accurate litigation summary cannot be produced.
Litigation summary and analysis for BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC. | 2:23-cv-02684
What patents are asserted in BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC., 2:23-cv-02684?
No asserted-patent list is present in the provided information, so a patent-by-patent litigation summary cannot be generated.
Which Orange Book-listed product and NDA/BLA are at issue?
No drug product, NDA/BLA number, or Orange Book listing details are included in the provided information, so the scope of the dispute cannot be determined.
Are the claims about formulations, methods of use, or manufacturing?
No claim categories, product attributes, or infringement theories are included in the provided information.
What relief is sought in BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC., 2:23-cv-02684?
No complaint relief details (injunction, damages, declaratory judgments) are included in the provided information.
Is this an ANDA Paragraph IV case or a patent infringement action outside ANDA?
The provided information does not specify the regulatory posture (ANDA, 505(b)(2), biosimilar, or other), so the legal framework cannot be analyzed.
How do BAUSCH HEALTH IRELAND LIMITED’s arguments compare with Taro’s defenses?
No briefing content, non-infringement/invalidity theories, or claim construction positions are included in the provided information.
What invalidity grounds are raised?
No invalidity grounds (anticipation, obviousness, written description, enablement, indefiniteness) are included in the provided information.
What non-infringement positions are raised?
No non-infringement claim comparisons, product design differences, or process differences are included in the provided information.
What is the procedural timeline for 2:23-cv-02684?
No procedural milestones (complaint filing date, answer date, Rule 12 motions, Markman schedule, summary judgment dates, trial dates) are included in the provided information.
When did the case reach Markman/claim construction?
No claim construction timeline is included in the provided information.
What motions were decided?
No motion rulings are included in the provided information.
Has there been a settlement in BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC., 2:23-cv-02684?
No settlement terms, consent judgments, or dismissal orders are included in the provided information.
Did any party agree to an entry-for-amendment date or launch prohibition?
No FDA entry timing or agreed launch dates are included in the provided information.
Are there any covenants not to sue affecting generic launch risk?
No covenants or releases are included in the provided information.
What does the docket indicate about who is winning so far?
No docket disposition (dismissal, stay, summary judgment, sanctions, or ongoing trial track) is included in the provided information.
How do potential licensing terms affect commercial exposure for Taro?
No licensing or manufacturing/technology transfer terms are included in the provided information.
What generic entry risks exist for Taro under the disputed IP?
No Orange Book exclusivity status, remaining patent term, or litigation stay status is included in the provided information.
What is the FDA regulatory status linked to 2:23-cv-02684?
No FDA filing detail is included in the provided information, so Orange Book status and FDA pathway risk cannot be analyzed.
Is the defendant tied to an ANDA Paragraph IV notice?
No Paragraph IV notice details are included in the provided information.
Is the dispute tied to pediatric exclusivity, 3-year/5-year exclusivity, or a 180-day exclusivity trigger?
No exclusivity trigger details are included in the provided information.
Key takeaways
- A litigation summary and analysis for BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC., 2:23-cv-02684 cannot be produced from the provided record because it contains no asserted-patent list, no procedural posture, no court rulings, and no settlement or FDA-linked details.
- Any attempt to identify patents, outcomes, or launch implications from the case caption alone would be incomplete and would not support business- or litigation-grade decision-making.
FAQs
What court is handling BAUSCH HEALTH IRELAND LIMITED v. TARO PHARMACEUTICALS INC., 2:23-cv-02684?
Not determinable from the provided information.
What patents does Bausch Health Ireland Limited allege Taro infringes in 2:23-cv-02684?
Not determinable from the provided information.
Has the court stayed the case pending PTO reexamination or IPR?
Not determinable from the provided information.
What is the status of any motions to dismiss or summary judgment in 2:23-cv-02684?
Not determinable from the provided information.
When is the next scheduled litigation event in 2:23-cv-02684?
Not determinable from the provided information.
References
- PACER/Docket reference for Bausch Health Ireland Limited v. Taro Pharmaceuticals Inc., 2:23-cv-02684. (Not provided in the input record.)
